{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:45:28Z","timestamp":1790343928098,"version":"4.1.0"},"reference-count":75,"publisher":"Informa UK Limited","issue":"18","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,6,5]]},"DOI":"10.2217\/fon-2023-0679","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T13:28:34Z","timestamp":1713533314000},"page":"1251-1266","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":36,"title":["Belzutifan: a novel therapeutic for the management of von Hippel\u2013Lindau disease and beyond"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-5716","authenticated-orcid":false,"given":"Lauren","family":"Curry","sequence":"first","affiliation":[{"name":"Division of Medical Oncology; British Columbia Cancer\u2013Vancouver Cancer Centre\/University of British Columbia, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1399-5946","authenticated-orcid":false,"given":"Maryam","family":"Soleimani","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology; British Columbia Cancer\u2013Vancouver Cancer Centre\/University of British Columbia, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1279"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000831"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103750"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29080429"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15728"},{"key":"e_1_3_4_8_1","doi-asserted-by":"crossref","unstructured":"Latif F Tory K Gnarra J et al. Identification of the von Hippel\u2013Lindau disease tumor suppressor gene.2605(112) 1317\u20131320 (1993).","DOI":"10.1126\/science.8493574"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1925248"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-838235"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/35017054"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00767"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1073440"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7660122"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.2.732"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5414.657"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10409238.2013.838205"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.01.005"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.04.006"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01354-5"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215313"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34896"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00544-5"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-104058"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr011"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30487-X"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","unstructured":"Pili\u00e9 P Hasanov E Matin SF et al. Pilot study of dovitinib in patients with von Hippel\u2013Lindau disease. 9(34) 23390\u201323395 (2018).","DOI":"10.18632\/oncotarget.25171"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103425"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010818-021637"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00487-9"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.09.008"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0473"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19795"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19796"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.2627"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00719"},{"key":"e_1_3_4_37_1","unstructured":"US Food and Drug Administration. Highlights of prescribing information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215383s000lbl.pdf"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01606-x"},{"key":"e_1_3_4_39_1","unstructured":"Clinicaltrials.gov. Belzutifan (MK-6482) hepatic impairment study (MK-6482-020). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04995484"},{"key":"e_1_3_4_40_1","unstructured":"Clinicaltrials.gov. A study of belzutifan (MK-6482) in participants with renal impairment (MK-6482-021). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04994522"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01324-7"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-14"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133194"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201710-2079OC"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay9452"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1101\/2022.07.11.499380"},{"key":"e_1_3_4_47_1","doi-asserted-by":"crossref","unstructured":"Iliopoulos O Bundsbaek A Iversen B et al. Belzutifan treatment for von Hippel\u2013Lindau (VHL) disease-associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study. 411(Suppl. 6) 2008 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.2008"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.074"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.733"},{"key":"e_1_3_4_50_1","unstructured":"US Food and Drug Administration. FDA approves belzutifan for cancers associated with von Hippel\u2013Lindau disease (2021). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease"},{"key":"e_1_3_4_51_1","unstructured":"Drug and Health Product Portal. Regulatory Decision Summary for Welireg (2022). https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS01061"},{"key":"e_1_3_4_52_1","unstructured":"Medicines and Healthcare products Regulatory Agency. Orphan register: Welireg. www.gov.uk\/government\/publications\/orphan-registered-medicinal-products\/orphan-register#welireg"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS748"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00097-9"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1550"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS399"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"e_1_3_4_59_1","doi-asserted-by":"crossref","unstructured":"Jonasch E Bauer TM Papadopoulos KP et al. 4509 Poster Discussion Session Phase 1 LITESPARK-001 (MK-6482-001) study ofbelzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.","DOI":"10.1200\/JCO.2022.40.16_suppl.4509"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS368"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.090"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4553"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0802"},{"key":"e_1_3_4_64_1","unstructured":"Clinicaltrials.gov. Belzutifan\/MK-6482 for the treatment of advanced pheochromocytoma\/paraganglioma (PPGL) pancreatic neuroendocrine tumor (pNET) von-Hippel-Lindau (VHL) disease-associated tumors advanced gastrointestinal stromal tumor (wt GIST) or solid tumors with HIF-2a related genetic alterations (MK-6482-015). https:\/\/clinicaltrials.gov\/study\/NCT04924075"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.586857"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS669"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb03196.x"},{"key":"e_1_3_4_68_1","unstructured":"Clinicaltrials.gov. A neoadjuvant study of abiraterone acetate leuprolide acetate and belzutifan in men with regional prostate cancer. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05574712"},{"key":"e_1_3_4_69_1","unstructured":"Clinicaltrials.gov. Study of pembrolizumab (MK-3475) combination therapies in metastatic castration-resistant prostate cancer (MK-3475-365\/KEYNOTE-365). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02861573"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110051"},{"key":"e_1_3_4_71_1","unstructured":"Lively B. Investigators look to overcome resistance in advanced HCC with triplet combinations (2021). www.onclive.com\/view\/investigators-look-to-overcome-resistance-in-advanced-hcc-with-triplet-combinations"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041048"},{"key":"e_1_3_4_73_1","unstructured":"Clinicaltrials.gov. [A study of belzutifan (MK-6482) in combination with palbociclib versus belzutifan monotherapy in participants with advanced renal cell carcinoma (MK-6482-024\/LITESPARK-024).ABEMA alone or in combination with MK-6482.]. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05468697; https:\/\/clinicaltrials.gov\/study\/NCT04627064"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.416"},{"key":"e_1_3_4_75_1","unstructured":"Clinicaltrials.gov. A study of belzutifan (MK-6482) in participants with advanced clear cell renal cell carcinoma (MK-6482-018). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04846920"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1159\/000453198"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14704"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T21:37:16Z","timestamp":1727213836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":75,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,6,5]]}},"alternative-id":["10.2217\/fon-2023-0679"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0679","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}